Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2). These data, from the global Phase 1/2 ReFocus study in patients with FGFR2-altered cholangiocarcinoma (CCA) and multiple other solid tumors, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023. The data being presented at ASCO are generally consistent with those previously reported at the European Society for Medical Oncology (ESMO) Congress in September 2022.
Here’s How Much $100 Invested In ASML Holding 20 Years Ago Would Be Worth Today
ASML Holding (NASDAQ:ASML) has outperformed the market over the past 20 years by 12.18% on an annualized basis producing an average annual return of 20.02%. Currently, ASML Holding has a market capitalization of $228.77 billion.
